Long-Term Investments (Tables)
|
6 Months Ended |
Jun. 30, 2022 |
Long Term Investment [Abstract] |
|
Schedule of ownership percentages of investee |
| |
Ownership percentage | | |
|
| |
June 30, | | |
December 31, | | |
Accounting |
Name of related party | |
2022 | | |
2021 | | |
treatments |
Braingenesis Biotechnology Co., Ltd. | |
| 0.17 | % | |
| 0.17 | % | |
Cost Method |
Genepharm Biotech Corporation | |
| 0.70 | % | |
| 0.70 | % | |
Cost Method |
BioHopeKing Corporation | |
| 5.90 | % | |
| 5.90 | % | |
Cost Method |
BioFirst Corporation | |
| 15.99 | % | |
| 15.99 | % | |
Equity Method |
Rgene Corporation | |
| 31.62 | % | |
| 31.62 | % | |
Equity Method |
|
Schedule of extent the investee relies |
Name of related party |
|
The extent the investee relies on the Company for its business |
Braingenesis Biotechnology Co., Ltd. |
|
No specific business relationship |
Genepharm Biotech Corporation |
|
No specific business relationship |
BioHopeKing Corporation |
|
Collaborating with the Company to develop and commercialize drugs |
BioFirst Corporation |
|
Collaborating with the Company to develop and commercialize drugs |
Rgene Corporation |
|
Collaborating with the Company to develop and commercialize drugs |
|
Schedule of long-term investment |
| |
June 30, 2022 | | |
December 31, 2021 | |
| |
(Unaudited) | | |
| |
Non-marketable Cost Method Investments, net | |
| | |
| |
Braingenesis Biotechnology Co., Ltd. | |
$ | 7,411 | | |
$ | 7,941 | |
Genepharm Biotech Corporation | |
| 22,628 | | |
| 24,244 | |
BioHopeKing Corporation | |
| 840,532 | | |
| 900,570 | |
Sub total | |
| 870,571 | | |
| 932,755 | |
Equity Method Investments, net | |
| | | |
| | |
BioFirst Corporation | |
| - | | |
| - | |
Rgene Corporation | |
| - | | |
| - | |
Total | |
$ | 870,571 | | |
$ | 932,755 | |
|
Schedule of balance sheet |
| |
June 30, 2022 | | |
December 31, 2021 | |
| |
(Unaudited) | | |
| |
Current Assets | |
$ | 2,065,236 | | |
$ | 2,205,669 | |
Non-current Assets | |
| 877,630 | | |
| 959,454 | |
Current Liabilities | |
| 3,501,538 | | |
| 2,909,703 | |
Non-current Liabilities | |
| 113,615 | | |
| 32,522 | |
Stockholders’ Equity (Deficit) | |
| (672,287 | ) | |
| 222,898 | |
| |
June 30, 2022 | | |
December 31, 2021 | |
| |
(Unaudited) | | |
| |
Current Assets | |
$ | 1,227,904 | | |
$ | 73,452 | |
Noncurrent Assets | |
| 330,231 | | |
| 374,423 | |
Current Liabilities | |
| 2,221,846 | | |
| 1,934,786 | |
Noncurrent Liabilities | |
| - | | |
| - | |
Shareholders’ Deficit | |
| (663,711 | ) | |
| (1,486,911 | ) |
|
Schedule of statements of operation |
| |
Six Months Ended June 30, | |
| |
2022 | | |
2021 | |
| |
(Unaudited) | | |
| |
Net sales | |
$ | 15,398 | | |
$ | 13,500 | |
Gross profit | |
| 3,375 | | |
| 3,203 | |
Net loss | |
| (872,254 | ) | |
| (465,704 | ) |
Share of losses from investments accounted for using the equity method | |
| - | | |
| (101,382 | ) |
|
|
Six Months Ended
June 30, |
|
|
|
2022 |
|
|
2021 |
|
|
|
(Unaudited) |
|
Net sales |
|
$ |
- |
|
|
$ |
- |
|
Gross Profit |
|
|
- |
|
|
|
- |
|
Net loss |
|
|
(295,517 |
) |
|
|
(228,451 |
) |
Share of loss from investments accounted for using the equity method |
|
|
- |
|
|
|
- |
|
|
Schedule of equity investments |
| |
Six Months Ended June 30, | |
| |
2022 | | |
2021 | |
| |
(Unaudited) | |
Share of equity method investee losses | |
$ | - | | |
$ | (101,382 | ) |
|